The Brand Name HISTRIN Has Generic Salt :: Ephedrine 

HISTRIN  Is From Company Brooks Ph. Priced :: Rs. 30

HISTRIN have Ephedrine is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

Indications for Drugs ::

Bronchial asthma, Hypotension, Diabetic neuropathic oedema, Nasal congestion

Drug Dose ::

Adult: PO Diabetic neuropathic oedema 30-60 mg 3 times/day. IV Reversal of spinal or epidural anesth-induced hypotension As 3 mg/mL soln: 3-6 mg, up to 9 mg, may repeat every 3-4 mins if needed.

Contraindication ::

Hypersensitivity. Hypertension, thyrotoxicosis, BPH. Lactation.

Drug Precautions ::

Ischaemic heart disease, hyperthyroidism, diabetes mellitus, hypertension, angle-closure glaucoma, renal impairment; prostatic enlargement; pregnancy, elderly.

Drug Side Effects ::

Anxiety, tachycardia, tremor, dry mouth, hypertension, cardiac arrhythmias, impaired circulation to the extremities, nervousness, insomnia, palpitations. Difficulty in micturition in patients with prostatic enlargement. Nasal drops: Local irritation, rebound nasal congestion and drug-induced rhinitis on prolonged use. Potentially Fatal: Delusions, hallucinations. Seen with hypersensitivity and overdosage. Acute CNS and CVS stimulation presenting as vomiting, fever, hypertension, psychosis. Cardiac arrhythmias.

Pregnancy category ::

3

Drug Mode of Action ::  

Ephedrine has both ?- and ?-adrenergic acitivity with pronounced stimulating effects on the CNS. It increases cardiac output, induces peripheral vasoconstriction, bronchodilation, reduces intestinal tone and motility, and relaxes the bladder while contracting the sphincter muscle. It also has stimulant action on the resp center and dilates the pupil witho affecting light reflexes.

Drug Interactions ::

Reduces antihypertensive effect of bethanidine and guanethidine. May increase clearance of dexamethasone. Increased incidence of adverse effects when used with theophylline. Potentially Fatal: Severe HTN when combined with MAOIs or withi 2 wk of discontinuance of MAOI treatment. Increased risk of arrhythmias with cardiac glycosides, quinidine or tricyclic antidepressants. Increased vasoconstriction or pressor effects with ergot alkaloids or oxytocin.